ECE2007 Poster Presentations (1) (659 abstracts)
Resistin levels in hypothyroid patients before and after treatment &br;with thyroxin
Marianthi Tzoitou 1 , Evridiki Papadopoulou 1 , A Galactidou 2 , Athanasios Papageorgiou 1 , Anargyros Kourtis 1 , Marina Kita 1 , louiza ventzi 1 & Avraam Avramidis 1
1Endocrinology Department, Hippokratio General Hospital, Thessaloniki, Greece; 2Research Department of Theagenio Hospital, Thessaloniki, Greece.
Introduction: Resistin is a peptide hormone that is secreted from fat cells and its secretion is regulated from hormonal and dietary factors. In hypothyroid patients its levels are decreased.
The purpose of this study is to evaluate the levels of circulating resistin in hypothyroid patients before and after thyroid function is normalized with thyroxin therapy.
Materials and methods: Twenty (20) hypothyroid patients (2M, 18F) mean aged 49.9±12.4 and mean weight 75.1±19.4 Kgr) were studied.
FT4, TSH, AMA, ATA, Resistin were measured before and three months after thyroxin therapy.
Results: Resistin levels do not change significantly (5.8±4.1 vs 5.1±3.4 μg/lt).All patients became euthyroid after three months of treatment and TSH, FT4, AMA, ATA levels were changed significantly(16.7±3.4 miu/lt vs1.2±0.2 miu/lt, 0.8±0.07 ng/dl vs1.3±0.07 ng/dl and 1579.6±653 vs 412±219. 441.8±205 vs 264.8±111). The body weight of the patients was not change significantly during therapy( 75.1±19.4 vs 74.1±17.2 Kgr).
Conclusions: Normalization of thyroid function did not affect resistin levels significantly. Possibly this is because there was no change IN the patients weight during treatment.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more